Author:
Li Han,Su Weijuan,Zheng Zeyu,Li Jia,Wang Shunhua,Chen Zheng,Zhang Yuxian,Huang Bingkun,Lyu Fuping,Yan Fangfang,Huang Caoxin,Lin Mingzhu,Shi Xiulin,Li Xuejun
Reference24 articles.
1. The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms;E Massimino;Cells,2021
2. Metabolic profile and quality of life in class I sarcopenic overweight and obese postmenopausal women: a MONET study. Applied physiology, nutrition, and metabolism = Physiologie appliquee;V Messier;nutrition et metabolisme,2009
3. Sarcopenia and sarcopenic obesity classifications and cardiometabolic risks in older women;E P Dos Santos;Archives of gerontology and geriatrics,2014
4. Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives;C Koliaki;Current obesity reports,2019
5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY;W T Garvey;Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,2016